Diagnostic and prognostic value of serum miR‑145 and vascular endothelial growth factor in non‑small cell lung cancer

Geater,Sarayut Lucien; Chaniad,Pichitpon; Trakunram,Keson; Keeratichananont,Warangkana; Buya,Suhaimee; Thongsuksai,Paramee; Raungrut,Pritsana

doi:10.3892/ol.2021.13130

Diagnostic and prognostic value of serum miR‑145 and vascular endothelial growth factor in non‑small cell lung cancer

Authors:
- Sarayut Lucien Geater
- Pichitpon Chaniad
- Keson Trakunram
- Warangkana Keeratichananont
- Suhaimee Buya
- Paramee Thongsuksai
- Pritsana Raungrut
View Affiliations

Affiliations: Department of Internal Medicine, Songklanagarind Hospital, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand, Department of Biomedical Sciences and Biomedical Engineering, Songklanagarind Hospital, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand, Medical Data Center for Research and Innovation, Songklanagarind Hospital, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand, Department of Pathology, Songklanagarind Hospital, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
Published online on: November 11, 2021 https://doi.org/10.3892/ol.2021.13130
Article Number: 12
Copyright: © Geater et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have reported the diagnostic and prognostic value of serum microRNA (miR)‑145 and vascular endothelial growth factor (VEGF) levels in various types of cancer; however, their clinical use in non‑small cell lung cancer (NSCLC) remains unclear. The present study included 215 patients, 106 with NSCLC and 109 with other lung diseases (OLDs). miR‑145 expression levels were determined using reverse transcription‑quantitative PCR (RT‑qPCR) and VEGF levels were measured using an ELISA. The diagnostic performance was assessed using a receiver operating characteristic curve and area under the curve (AUC) analysis. A Kaplan‑Meier survival curve and Cox regression analysis were employed to evaluate the prognostic significance of the markers. The biological function of miR‑145 was examined in A549 and H1792 cell lines. The effects of miR‑145 on cell proliferation of NSCLC cells were evaluated by flow cytometry, and the expression levels of miR‑145 and cell cycle‑related genes were determined by RT‑qPCR. The results revealed that miR‑145 and VEGF exhibited fair diagnostic performance [AUC, 0.61 (95% CI, 0.55‑0.68) and AUC, 0.64 (95% CI, 0.57‑0.71), respectively]. Combining age and smoking status with miR‑145 and VEGF provided the best model for differentiating patients with NSCLC from those with OLDs (AUC, 0.76; 95% CI, 0.69‑0.83). Furthermore, low serum miR‑145 levels were associated with poor overall survival [hazard ratio (HR), 0.48; 95% CI, 0.27‑0.85], whereas high VEGF levels were not associated with poor overall survival (HR, 1.47; 95% CI, 0.81‑2.68). In addition, the results of the in vitro experiments indicated that miR‑145 decreased cell proliferation via the induction of cell cycle arrest. In conclusion, the findings of the present study suggested that combining miR‑145 and VEGF levels with clinical risk factors may be a potential diagnostic scheme for NSCLC. In addition, serum miR‑145 may be used as a prognostic marker. These results indicated that miR‑145 may function as a tumor suppressor in NSCLC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui R and Zhang X: Circulating MicroRNAs in Cancer: Potential and Challenge. Front Genet. 10:6262019. View Article : Google Scholar : PubMed/NCBI
3	Hirales Casillas CE, Flores Fernández JM, Padilla Camberos E, Herrera López EJ, Leal Pacheco G and Martínez Velázquez M: Current status of circulating protein biomarkers to aid the early detection of lung cancer. Future Oncol. 10:1501–1513. 2014. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
5	Xu W, Chang J, Du X and Hou J: Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer. Biomed Pharmacother. 95:1112–1118. 2017. View Article : Google Scholar : PubMed/NCBI
6	Zhang Y, Wen X, Hu XL, Cheng LZ, Yu JY and Wei ZB: Downregulation of miR-145-5p correlates with poor prognosis in gastric cancer. Eur Rev Med Pharmacol Sci. 20:3026–3030. 2016.PubMed/NCBI
7	Chang Y, Yan W, Sun C, Liu Q, Wang J and Wang M: miR-145-5p inhibits epithelial-mesenchymal transition via the JNK signaling pathway by targeting MAP3K1 in non-small cell lung cancer cells. Oncol Lett. 14:6923–6928. 2017.PubMed/NCBI
8	Wang M, Wang J, Deng J, Li X, Long W and Chang Y: MiR-145 acts as a metastasis suppressor by targeting metadherin in lung cancer. Med Oncol. 32:3442015. View Article : Google Scholar : PubMed/NCBI
9	Kieran MW, Kalluri R and Cho YJ: The VEGF pathway in cancer and disease: Responses, resistance, and the path forward. Cold Spring Harb Perspect Med. 2:a0065932012. View Article : Google Scholar : PubMed/NCBI
10	Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ, Jiang Y, Chen X, Qi Y, Zhang X, et al: MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle. 11:2137–2145. 2012. View Article : Google Scholar : PubMed/NCBI
11	Chaniad P, Trakunran K, Geater SL, Keeratichananont W, Thongsuksai P and Raungrut P: Serum miRNAs associated with tumor-promoting cytokines in non-small cell lung cancer. PLoS One. 15:e02415932020. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Ta WW, Sun PF, Meng YF and Zhao CZ: Diagnostic and prognostic significance of serum miR-145-5p expression in glioblastoma. Int J Clin Exp Pathol. 12:2536–2543. 2019.PubMed/NCBI
13	Liang H, Jiang Z, Xie G and Lu Y: Serum microRNA-145 as a novel biomarker in human ovarian cancer. Tumour Biol. 36:5305–5313. 2015. View Article : Google Scholar : PubMed/NCBI
14	Komatsu H, Oishi T, Itamochi H, Shimada M, Sato S, Chikumi J, Sato S, Nonaka M, Sawada M, Wakahara M, et al: Serum vascular endothelial growth factor-A as a prognostic biomarker for epithelial ovarian cancer. Int J Gynecol Cancer. 27:1325–1332. 2017. View Article : Google Scholar : PubMed/NCBI
15	Wang RJ, Zheng YH, Wang P and Zhang JZ: Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 8:765–771. 2015.PubMed/NCBI
16	Chakra M, Pujol JL, Lamy PJ, Bozonnat MC, Quantin X, Jacot W and Daurès JP: Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol. 3:1119–1126. 2008. View Article : Google Scholar : PubMed/NCBI
17	Shen H, Shen J, Wang L, Shi Z, Wang M, Jiang BH and Shu Y: Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer. Biomed Pharmacother. 69:301–305. 2015. View Article : Google Scholar : PubMed/NCBI
18	Akın Kabalak P, Çiledağ A, Demir N, Çelik G, Yüksel C, Köycü G, Gökmen Öztuna D, Taner A, Kaya A, Kutlay H, et al: Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer. Tuberk Toraks. 63:71–77. 2015. View Article : Google Scholar : PubMed/NCBI
19	Bossuyt PM: Clinical validity: Defining biomarker performance. Scand J Clin Lab Invest Suppl. 242:46–52. 2010. View Article : Google Scholar : PubMed/NCBI
20	Trakunram K, Chaniad P, Geater SL, Keeratichananont W, Chittithavorn V, Uttayamakul S, Buya S, Raungrut P and Thongsuksai P: Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer. Cancer Biol Med. 17:652–663. 2020. View Article : Google Scholar : PubMed/NCBI
21	Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al WHO Panel, : The 2015 World Health Organization Classification of Lung Tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
22	Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
23	Rao X, Huang X, Zhou Z and Lin X: An improvement of the 2ˆ(−delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 3:71–85. 2013.PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Li S, Wang L, Meng Y, Chang Y, Xu J and Zhang Q: Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients. Oncotarget. 8:41282–41293. 2017. View Article : Google Scholar : PubMed/NCBI
26	Jiang L, Hochwald S, Deng S, Chen Y, Tan C, Zhong Q and Huang H: Diagnostic and prognostic performance of serum vascular endothelial growth factor, vascular endothelial growth factor receptor 2, and osteopontin for gastrointestinal cancers. Clin Lab. 65:652019. View Article : Google Scholar
27	Zhang Y, Yu LK, Lu GJ, Xia N, Xie HY, Hu W, Hao KK, Xu CH and Qian Q: Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer. Asian Pac J Cancer Prev. 15:8435–8440. 2014. View Article : Google Scholar : PubMed/NCBI
28	Wozniak MB, Scelo G, Muller DC, Mukeria A, Zaridze D and Brennan P: Circulating microRNAs as non-invasive biomarkers for early detection of non-small-cell lung cancer. PLoS One. 10:e01250262015. View Article : Google Scholar : PubMed/NCBI
29	Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H and Fukurchi Y: Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung. 183:29–42. 2005. View Article : Google Scholar : PubMed/NCBI
30	Zeinali T, Karimi L, Hosseinahli N, Shanehbandi D, Mansoori B, Mohammadi A, Hajiasgharzadeh K, Babaloo Z, Majidi-Zolbanin J and Baradaran B: Overexpression of miRNA-145 induces apoptosis and prevents proliferation and migration of MKN-45 gastric cancer cells. EXCLI J. 19:1446–1458. 2020.PubMed/NCBI
31	Ding W, Tan H, Zhao C, Li X, Li Z, Jiang C, Zhang Y and Wang L: MiR-145 suppresses cell proliferation and motility by inhibiting ROCK1 in hepatocellular carcinoma. Tumour Biol. 37:6255–6260. 2016. View Article : Google Scholar : PubMed/NCBI
32	Pan Y, Ye C, Tian Q, Yan S, Zeng X, Xiao C, Wang L and Wang H: miR-145 suppresses the proliferation, invasion and migration of NSCLC cells by regulating the BAX/BCL-2 ratio and the caspase-3 cascade. Oncol Lett. 15:4337–4343. 2018.PubMed/NCBI
33	Ye Z, Shen N, Weng Y, Li K, Hu L, Liao H, An J, Liu L, Lao S and Cai S: Low miR-145 silenced by DNA methylation promotes NSCLC cell proliferation, migration and invasion by targeting mucin 1. Cancer Biol Ther. 16:1071–1079. 2015. View Article : Google Scholar : PubMed/NCBI
34	Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A and Hu J: miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 29:1512010. View Article : Google Scholar : PubMed/NCBI
35	Fan L, Wu Q, Xing X, Wei Y and Shao Z: MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai). 44:407–414. 2012. View Article : Google Scholar : PubMed/NCBI
36	Li YQ, He QM, Ren XY, Tang XR, Xu YF, Wen X, Yang XJ, Ma J and Liu N: MiR-145 inhibits metastasis by targeting fascin actin-bundling protein 1 in nasopharyngeal carcinoma. PLoS One. 10:e01222282015. View Article : Google Scholar : PubMed/NCBI